Under the contract, AMRI will focus on the development and manufacture of APIs and drug product for Phase I clinical studies.
AMRI, a global contract research, development, and manufacturing organization, has secured a seven-year contract from the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH), to develop and manufacture active pharmaceutical ingredients (APIs) and drug product for Phase I clinical studies, the company announced on June 6, 2018. The company will conduct the bulk of this work its Albany, NY, facilities.
“Our new contract with the NIH not only enhances AMRI’s ability to positively impact the health of the general public, but it also serves as a testament of our work, giving prospective customers confidence in our aptitude to solve complex scientific challenges,” noted Christopher Conway, senior vice president of discovery, development, and analytical services and fine chemicals, at AMRI, in a company press release. “We are excited for the opportunity to further support this well-respected government agency aimed at advancing their researchers’ programs.”
In addition to this contract, AMRI is also contracted to provide services to other NIH-funded researchers, including being selected as a dedicated chemical biology consortium (CBC) center for the National Cancer Institute experimental therapeutics program and programs for the National Center for Advancing Translational Sciences and the Blueprint Neurotherapeutics Network.
Source: AMRI
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.